WebMD Health Corp Logo

Print Print page   Email Email page   PDF Download PDF
« Previous Release | Next Release »



WebMD Reports Fourth Quarter and Full Year 2016 Financial Results

WebMD Issues 2017 Financial Guidance
WebMD Announces Exploration of Strategic Alternatives

NEW YORK, Feb. 16, 2017 /PRNewswire/ -- WebMD Health Corp. (NASDAQ: WBMD), the leading source of health information, today announced fourth quarter and full year financial results for 2016.

"We are pleased to report fourth quarter and full year results near the high end of our expectations," said Steve Zatz, Chief Executive Officer, WebMD. "The future of health care is undeniably tied to digital interactions and, as the leading online service for physicians and consumers, we believe that WebMD will be a vital force in shaping that future."

Financial Highlights

For the three months ended December 31, 2016:

For the year ended December 31, 2016:

Balance Sheet Highlights

As of December 31, 2016, WebMD had: approximately $991 million in investments and cash and cash equivalents; $1.06 billion in aggregate principal amount of convertible notes outstanding; and approximately 37.6 million shares of its common stock outstanding (including approximately 900 thousand unvested shares of restricted stock).

During the fourth quarter, the company utilized $110 million of cash to purchase 2.0 million shares of its common stock in a tender offer. The Company also utilized $1.2 million of cash to purchase approximately 24 thousand shares of its common stock under its stock repurchase program. As of December 31, 2016, approximately $45.6 million remained available for repurchases under WebMD's stock repurchase program. Under its stock repurchase program, WebMD may repurchase shares from time to time in the open market, through block trades or in private transactions, depending on market conditions and other factors.

Traffic Highlights

Traffic to the WebMD Health Network during the fourth quarter of 2016 averaged 179.5 million unique users per month, generating 3.63 billion page views for the quarter, representing decreases of 11% and 9% in users and page views, respectively, when compared to the prior year period.

Financial Guidance

Today WebMD issued financial guidance for the first quarter and full year 2017. For the full year ending December 31, 2017, WebMD expects:

Mr. Zatz continued, "Our financial outlook for this year reflects ongoing uncertainty in the healthcare landscape. While we are not satisfied with the growth we are projecting at the present time for 2017, we remain positive about the longer term opportunity and believe that, as demand for digital health services continues to grow, WebMD and Medscape are uniquely positioned as the market leaders with strong brands, unparalleled engagement of consumer health and physician audiences, and a proven ability to demonstrate value to our customers." 

Based on the expected timing of delivery for customer programs, WebMD expects advertising and sponsorship revenue to be flat to slightly down in the first quarter of 2017 with growth occurring over the balance of 2017.

For the first quarter of 2017, WebMD expects:

A schedule summarizing the Company's financial guidance is attached to this press release.

Exploration of Strategic Alternatives

In a separate release issued today, WebMD announced that its Board of Directors, working together with its management team and legal and financial advisors, has commenced a process to explore and evaluate potential strategic alternatives focused on maximizing shareholder value. These alternatives could include, among other things, the sale of part or all of the Company, a merger with another party or other strategic transaction or continuing to execute on WebMD's business plan.

J.P. Morgan Securities LLC is acting as financial advisor to the Company. Shearman & Sterling LLP is acting as legal advisor.

Analyst and Investor Conference Call                                  

WebMD will hold a conference call with investors and analysts at 4:45 p.m. (Eastern) today. The call can be accessed at www.wbmd.com (in the Investor Relations section). A replay of the audio webcast will be available at the same web address.

About WebMD

WebMD Health Corp. (NASDAQ: WBMD) is the leading provider of health information services, serving consumers, physicians, healthcare professionals, employers, and health plans through our public and private online portals, mobile platforms and health-focused publications.

The WebMD Health Network includes WebMD.com, Medscape.com, MedicineNet.com, eMedicineHealth.com, RxList.com, OnHealth.com, Medscape Education (Medscape.org) and other WebMD owned sites and apps.

*****************************

All statements contained in this press release and the related analyst and investor conference call, other than statements of historical fact, are forward-looking statements, including those regarding:  explorations of possible transactions and other strategic alternatives; guidance on our future financial results and other projections or measures of our future performance; market opportunities or momentum and our ability to capitalize on them; and the benefits expected from new or expected contracts with customers, from new or updated products or services and from other potential sources of additional revenue. These statements speak only as of the date of this press release, are based on our current plans and expectations, and involve risks and uncertainties that could cause actual future events or results to be different than those described in or implied by such forward-looking statements. These risks and uncertainties include those relating to: the nature and timing of any possible transaction or other strategic alternative or of any potential benefits from any such transaction or other alternative; market acceptance of our products and services; our relationships with customers and other factors affecting their use of our services and the timing of entry into and implementation of specific contracts with customers, including regulatory matters affecting their products and services; our ability to deploy new or updated services and to create new or enhanced revenue streams from those services; our ability to attract and retain qualified personnel; and changes in economic, political or regulatory conditions or other trends affecting the healthcare, Internet and information technology industries.  Further information about these matters can be found in our Securities and Exchange Commission filings and this press release is intended to be read in conjunction with information contained in those filings. Except as required by applicable law or regulation, we do not undertake any obligation to update our forward-looking statements to reflect future events or circumstances.

*************************************

This press release, and the accompanying tables, include both financial measures in accordance with accounting principles generally accepted in the United States of America, or GAAP, as well as certain non-GAAP financial measures.  The tables attached to this press release include reconciliations of these non-GAAP financial measures to GAAP financial measures. In addition, an "Explanation of Non-GAAP Financial Measures" is attached to this press release as Annex A. 

*****************************

WebMD®, Medscape®, CME Circle®, Medpulse®, eMedicine®, MedicineNet®, theheart.org® and RxList® are among the trademarks of WebMD Health Corp. or its subsidiaries.

 

 

WEBMD HEALTH CORP.

CONSOLIDATED STATEMENTS OF OPERATIONS

 (In thousands, except per share data, unaudited)















Three Months Ended


Years Ended






December 31,


December 31,






2016


2015


2016


2015














Revenue




$    207,472


$    192,129


$    705,046


$    636,399


Cost of operations




72,895


69,475


266,654


247,311


Sales and marketing




41,328


40,129


145,962


138,025


General and administrative




23,397


24,183


91,141


91,580


Depreciation and amortization




7,721


7,418


30,792


30,521


Interest income




938


15


2,545


51


Interest expense




7,066


5,099


24,496


23,123


Loss on convertible notes


-


-


-


2,058


Gain on investments


-


-


-


139


Other expense


-


-


1,712


4,100


























Income before income tax provision


56,003


45,840


146,834


99,871


     Income tax provision


19,815


18,379


55,530


35,847


Net income


$      36,188


$      27,461


$      91,304


$      64,024


























Net income per common share:










     Basic


$          0.95


$          0.75


$          2.41


$          1.75


     Diluted


$          0.73


$          0.60


$          1.97


$          1.48














Weighted-average shares outstanding used in 








     computing income per common share: 










     Basic


38,006


36,583


37,854


36,600


     Diluted 


55,211


51,338


54,179


52,653














 

 

 

WEBMD HEALTH CORP.

CONSOLIDATED SUPPLEMENTAL FINANCIAL INFORMATION

 (In thousands, unaudited)



























Three Months Ended


Years Ended






December 31,


December 31,






2016


2015


2016


2015


Revenue










Advertising and sponsorship










     Biopharma and medical device


$      132,166


$      119,528


$      428,519


$      371,220


     OTC, CPG and other


38,847


38,758


132,754


127,805






171,013


158,286


561,273


499,025


Health services


28,803


27,218


113,937


110,441


Information services


7,656


6,625


29,836


26,933






$      207,472


$      192,129


$      705,046


$      636,399


























Net income


$        36,188


$        27,461


$        91,304


$        64,024














Interest, taxes, non-cash and other items  (a)










     Interest income


(938)


(15)


(2,545)


(51)


     Interest expense


7,066


5,099


24,496


23,123


     Income tax provision


19,815


18,379


55,530


35,847


     Depreciation and amortization 


7,721


7,418


30,792


30,521


     Non-cash stock-based compensation


8,291


9,012


29,329


33,743


     Loss on convertible notes


-


-


-


2,058


     Gain on investments


-


-


-


(139)


     Other expense


-


-


1,712


4,100














Earnings before interest, taxes, non-cash










    and other items ("Adjusted EBITDA") (b)


$        78,143


$        67,354


$      230,618


$      193,226














(a)  Reconciliation of net income to Adjusted EBITDA.




(b)  See Annex A-Explanation of Non-GAAP Financial Measures.
















 

 

 

WEBMD HEALTH CORP.

CONDENSED CONSOLIDATED BALANCE SHEETS

 (In thousands)










December 31,




2016


2015




(unaudited)



Assets





Cash and cash equivalents


$          492,424


$        641,165

Accounts receivable, net


179,454


174,313

Investments


498,500


-

Prepaid expenses and other current assets


15,294


18,998


Total current assets


1,185,672


834,476







Property and equipment,  net


83,296


81,027

Goodwill


202,980


202,980

Intangible assets, net


7,774


10,894

Deferred tax assets, net


14,544


15,694

Other assets


6,920


10,852

Total Assets


$       1,501,186


$     1,155,923







Liabilities and Stockholders' Equity





Accrued expenses


$            78,597


$          80,664

Deferred revenue


105,310


102,715

2.25% convertible notes due 2016, net


-


102,523


Total current liabilities


183,907


285,902







2.50% convertible notes due 2018, net


398,066


396,281

1.50% convertible notes due 2020, net


295,432


294,266

2.625% convertible notes due 2023, net


351,190


-

Other long-term liabilities


28,731


23,246







Stockholders' equity


243,860


156,228







Total Liabilities and Stockholders' Equity


$       1,501,186


$     1,155,923







 

 

 

WEBMD HEALTH CORP.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands, unaudited)























Years Ended







December 31,







2016


2015

Cash flows from operating activities:






Net income


$           91,304


$        64,024


Adjustments to reconcile net income to net cash provided by






  operating activities:







Depreciation and amortization


30,792


30,521



Non-cash interest, net


3,906


4,172



Non-cash stock-based compensation


29,329


33,743



Deferred income taxes


1,083


(7,713)



Loss on convertible notes


-


2,058



Gain on investments


-


(139)



Changes in operating assets and liabilities:








Accounts receivable


(5,141)


(37,507)




Prepaid expenses and other, net


4,039


(4,132)




Accrued expenses and other long-term liabilities


3,246


9,606




Deferred revenue


2,595


12,930





Net cash provided by operating activities


161,153


107,563










Cash flows from investing activities:






Purchases of property and equipment


(29,785)


(48,372)


Purchases of investments


(1,446,410)


-


Maturity of investments


948,078


139


Partial redemption of cost-method investment


2,599


-





Net cash used in investing activities


(525,518)


(48,233)










Cash flows from financing activities:






Proceeds from exercise of stock options


65,309


21,939


Cash used for withholding taxes due on stock-based awards


(17,599)


(6,438)


Net proceeds from issuance of convertible notes


350,394


-


Maturity of convertible notes


(102,682)


(151,038)


Repurchase of shares through tender offers


(110,413)


-


Purchases of treasury stock 


(23,643)


(28,406)


Excess tax benefit on stock-based awards


54,258


39,002





Net cash provided by (used in) financing activities


215,624


(124,941)

Net decrease in cash and cash equivalents


(148,741)


(65,611)

Cash and cash equivalents at beginning of period


641,165


706,776

Cash and cash equivalents at end of period


$         492,424


$      641,165










 

 

 

WEBMD HEALTH CORP.

NET INCOME PER COMMON SHARE

 (In thousands, except per share data, unaudited)



























Three Months Ended


Years Ended





December 31,


December 31,





2016


2015


2016


2015













Numerator:










Net income - Basic


$        36,188


$           27,461


$        91,304


$        64,024



Interest expense on 1.50% convertible notes, net of tax


878


864


3,513


3,456



Interest expense on 2.50% convertible notes, net of tax


1,827


1,797


7,307


7,189



Interest expense on 2.25% convertible notes, net of tax


-


449


457


3,460



Interest expense on 2.625% convertible notes, net of tax


1,676


-


3,911


-


Net income - Diluted


$        40,569


$           30,571


$      106,492


$        78,129
























Denominator:










Weighted-average shares - Basic


38,006


36,583


37,854


36,600



Stock options and restricted stock


1,158


1,427


1,658


1,412



1.50% convertible notes


5,699


5,694


5,695


5,694



2.50% convertible notes


6,210


6,205


6,206


6,205



2.25% convertible notes


-


1,429


353


2,742



2.625% convertible notes


4,138


-


2,413


-


Adjusted weighted-average shares after assumed conversions - Diluted


55,211


51,338


54,179


52,653
























Net income per common share:











Basic


$            0.95


$               0.75


$            2.41


$            1.75



Diluted


$            0.73


$               0.60


$            1.97


$            1.48












 

 

 











WEBMD HEALTH CORP.

FINANCIAL GUIDANCE FOR THE YEAR ENDING DECEMBER 31, 2017

(In millions, except per share amounts)














Guidance Range





Revenue









     Advertising and sponsorship









       Biopharma and medical device


$       437.0


$      450.0





       OTC, CPG and other


143.0


148.0








580.0


598.0





     Health services


99.0


100.0





     Information services


31.0


32.0








$       710.0


$      730.0















Net income


$         89.0


$        98.0















Interest, taxes, non-cash and other items (a)









   Interest expense, net


21.0


21.0





   Income tax provision (d)


54.0


60.0





   Depreciation and amortization


32.0


30.0





   Non-cash stock-based compensation


37.0


34.0















Earnings before interest, taxes, non-cash and other items ("Adjusted EBITDA") (b)


$       233.0


$      243.0















Income per share:









     Basic


$         2.41


$        2.61





     Diluted (c)


$         1.97


$        2.10















Calculation of income per share:










Net income (numerator for basic income per share)


$         89.0


$        98.0






Add-back of interest expense, net of tax, related to:










   1.50% convertible notes


3.5


3.5






   2.50% convertible notes


7.3


7.3






   2.625% convertible notes


6.7


6.7






Numerator for diluted income per share


$       106.5


$      115.5
















Weighted average shares outstanding (denominator for basic income per share)


37.0


37.5






Stock options and restricted stock


1.0


1.5






Weighted average shares issuable upon conversion of:










   1.50% convertible notes


5.7


5.7






   2.50% convertible notes


6.2


6.2






   2.625% convertible notes


4.2


4.2






Denominator for diluted income per share


54.1


55.1















(a) Reconciliation of net income to Adjusted EBITDA.



















(b) See Annex A - Explanation of Non-GAAP Financial Measures.














(c) See Supplemental 2017 Guidance for Income Per Share Calculation below.














(d) Effective January 1, 2017, the Company will adopt a new accounting standard which requires excess tax benefits or deficiencies resulting from stock award activity to be included within the income tax provision.  The income tax provision included in the 2017 financial guidance (including the Q1 2017 guidance provided below) excludes any adjustments related to this new accounting standard because the adjustments will be based on actual exercise or settlement activity, which cannot be estimated at this time.


Additional information regarding forecast for the quarter ending March 31, 2017:




-

Revenue is forecasted to be between $151 million to $154 million.















-

Revenue distribution is forecasted to be:  approximately 58.5% from Advertising and sponsorship - Biopharma and medical device; 21% from Advertising and sponsorship - OTC, CPG and other; 15.5% from health services; and 5% from information services.












-

Net income is forecasted to be between $9.8 million to $11.5 million.














-

Adjusted EBITDA is forecasted to be between $38 million to $40 million.














-

In calculating Adjusted EBITDA, the Company excluded the following expense items that are included in the calculation of Net Income: interest expense, net of $5.3 million; depreciation and amortization of $7.4 to $7.0 million; non-cash stock-based compensation of $9.3 to $8.9 million; and income tax provision of $6.2 to $7.3 million.  See Annex A - Explanation of Non-GAAP Financial Measures.












The above guidance does not include the impact, if any, of future deployment of capital for items such as share

repurchases, convertible note repurchases or acquisitions, gains or losses from discontinued operations, and

other non-recurring, one-time or unusual items (including the strategic review announced in the accompanying press release).

 

 

 

WEBMD HEALTH CORP.


SUPPLEMENTAL 2017 GUIDANCE FOR INCOME PER SHARE CALCULATION















Based on the Company's Financial Guidance for the Year Ending December 31, 2017, the 1.50% convertible notes, the 2.50% convertible notes and the 2.625% convertible notes are expected to be dilutive to net income on both the low end and high end of the full year guidance range.  Additionally, the 1.50% convertible notes, the 2.50% convertible notes and the 2.625% convertible notes may be dilutive in certain future quarters, depending on the amount of net income for such quarter.  The following table contains the approximate level of net income for an individual future quarter and for the full year 2017 at which each of the series of convertible notes would become dilutive to income per share. To the extent this net income is exceeded for any such period, the table also includes the amounts by which the numerator and denominator should each be adjusted for purposes of the diluted income per share calculation.















Quarterly Amounts


Annual Amounts


All amounts in millions

1.50% Convertible Notes


2.50% Convertible Notes


2.625% Convertible Notes


1.50% Convertible Notes


2.50% Convertible Notes


2.625% Convertible Notes















Approximate net income at which convertible notes  become dilutive  (a)

$                5.8


$              11.9


$              17.5


$              23.3


$              47.7


$              69.8















Interest expense, net of tax to add-back to net income (numerator)

$                0.9


$                1.8


$                1.7


$                3.5


$                7.3


$                6.7















Additional shares to include in weighted-
average diluted share count (denominator)

5.7


6.2


4.2


5.7


6.2


4.2















(a)  These net income amounts assume a weighted-average diluted share count of  38.0 million shares attributable to common shares, stock options and restricted stock (prior to the effect of convertible notes) and are subject to change as such weighted-average share count changes for a given quarter or annual period.

 

 

ANNEX A

Explanation of Non-GAAP Financial Measures

The accompanying WebMD Health Corp. press release and attachments include both financial measures in accordance with U.S. generally accepted accounting principles, or GAAP, as well as non-GAAP financial measures.  The non-GAAP financial measures represent earnings before interest, taxes, non-cash and other items (which we refer to as "Adjusted EBITDA").  Adjusted EBITDA should be viewed as supplemental to, and not as an alternative for net income or loss calculated in accordance with GAAP (referred to below as "net income").  The attachments to the press release include reconciliations of non-GAAP financial measures to GAAP financial measures. 

Adjusted EBITDA is used by our management as an additional measure of our company's performance for purposes of business decision-making, including developing budgets, managing expenditures, and evaluating potential acquisitions or divestitures.  Period-to-period comparisons of Adjusted EBITDA help our management identify additional trends in our company's financial results that may not be shown solely by period-to-period comparisons of net income.  In addition, we may use Adjusted EBITDA in the incentive compensation programs applicable to some of our employees in order to evaluate our company's performance.  Our management recognizes that Adjusted EBITDA has inherent limitations because of the excluded items, particularly those items that are recurring in nature.  In order to compensate for those limitations, management also reviews the specific items that are excluded from Adjusted EBITDA, but included in net income, as well as trends in those items.  The amounts of those items are set forth, for the applicable periods, in the reconciliations of Adjusted EBITDA to net income that accompany our press releases and disclosure documents containing non-GAAP financial measures, including the reconciliations contained in the accompanying press release attachments.

We believe that the presentation of Adjusted EBITDA is useful to investors in their analysis of our results for reasons similar to the reasons why our management finds it useful and because it helps facilitate investor understanding of decisions made by management in light of the performance metrics used in making those decisions.  In addition, as more fully described below, we believe that providing Adjusted EBITDA, together with a reconciliation of Adjusted EBITDA to net income, helps investors make comparisons between our company and other companies that may have different capital structures, different effective income tax rates and tax attributes, different capitalized asset values and/or different forms of employee compensation.  However, Adjusted EBITDA is intended to provide a supplemental way of comparing our company with other public companies and is not intended as a substitute for comparisons based on net income.  In making any comparisons to other companies, investors need to be aware that companies use different non-GAAP measures to evaluate their financial performance.  Investors should pay close attention to the specific definition being used and to the reconciliation between such measures and the corresponding GAAP measures provided by each company under applicable SEC rules.

The following is an explanation of the items excluded by us from Adjusted EBITDA but included in net income:

 






Three Months Ended


Year Ended






December 31,


December 31,






2016

2015


2016

2015








Non-cash stock-based compensation included in:







Cost of operations


$    1,509

$    1,426


$    5,216

$    5,217


Sales and marketing


$    1,647

$    2,191


$    5,942

$    7,290


General and administrative


$    5,135

$    5,395


$  18,171

$  21,236












 

 






Three Months Ended


Year Ended






December 31,


December 31,






2016

2015


2016

2015








Non-cash interest expense







2.25% Convertible Notes


$            —

$       159


$         159

$    1,221


2.50% Convertible Notes


$         446

$       446


$      1,785

$    1,785


1.50% Convertible Notes


$         291

$       291


$      1,166

$    1,166


2.625% Convertible Notes


$         342

$          —


$         796

$          —

 

Cash interest expense








2.25% Convertible Notes


$            —

$       578


$         577

$    4,451


2.50% Convertible Notes


$      2,500

$    2,500


$    10,000

$  10,000


1.50% Convertible Notes


$      1,125

$    1,125


$      4,500

$    4,500


2.625% Convertible Notes


$      2,362

$          —


$      5,513

$          —












 

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/webmd-reports-fourth-quarter-and-full-year-2016-financial-results-300409091.html

SOURCE WebMD Health Corp.

News Provided by Acquire Media

Close window | Back to top